Intersect ENT, Inc. (XENT)
(Delayed Data from NSDQ)
$23.70 USD
-0.30 (-1.25%)
Updated Mar 3, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value C Growth D Momentum D VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XENTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect strength at MiSight 1-day contact lens.
COONegative Net Change XENTNegative Net Change SURFNegative Net Change HEXONegative Net Change
earnings medical
What's in Store for Patterson Companies' (PDCO) Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Dental segment.
PDCONegative Net Change XENTNegative Net Change SURFNegative Net Change HEXONegative Net Change
medical
Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal fourth-quarter results are likely to reflect solid show by its segments and robust product portfolio.
XENTNegative Net Change VEEVNegative Net Change SURFNegative Net Change HEXONegative Net Change
medical
Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
by Zacks Equity Research
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
HOLXNegative Net Change ABTNegative Net Change IDXXNegative Net Change XENTNegative Net Change
medical
Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing
by Zacks Equity Research
Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.
HOLXNegative Net Change PKINegative Net Change IDXXNegative Net Change XENTNegative Net Change
medical
Intersect ENT (XENT) Banks on SINUVA Sales Amid COVID-19 Woes
by Zacks Equity Research
Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.
MCKNegative Net Change MMSINegative Net Change PDCONegative Net Change XENTNegative Net Change
medical
Intersect ENT (XENT) Up 17.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
XENTNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.
ALGNNegative Net Change TMONegative Net Change WSTNegative Net Change XENTNegative Net Change
earnings medical
Intersect ENT (XENT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of 22.73% and 0.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
XENTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Intersect ENT (XENT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XENTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View
by Zacks Equity Research
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
QGENNegative Net Change BSXPositive Net Change TMONegative Net Change XENTNegative Net Change
medical
Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement
by Zacks Equity Research
Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.
HOLXNegative Net Change QGENNegative Net Change TMONegative Net Change XENTNegative Net Change
medical
Why Is Intersect ENT (XENT) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
XENTNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates
by Zacks Equity Research
Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.
HOLXNegative Net Change TMONegative Net Change WSTNegative Net Change XENTNegative Net Change
earnings medical
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -30.00% and 24.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
XENTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XENTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Implied Volatility Surging for Intersect ENT (XENT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.
XENTNegative Net Change
medical
Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS
by Zacks Equity Research
This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.
HOLXNegative Net Change QGENNegative Net Change XENTNegative Net Change APHANegative Net Change
medical
Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.
BIIBNegative Net Change LLYNegative Net Change XENTNegative Net Change APHANegative Net Change
earnings medical
Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -20.00% and 0.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
XENTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Preview: Intersect ENT (XENT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XENTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Moving Average Crossover Alert: Intersect ENT
by Zacks Equity Research
Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
XENTNegative Net Change
medical
Intersect Posts Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.
DXCMNegative Net Change SRDXPositive Net Change RMDNegative Net Change XENTNegative Net Change
medical
Intersect ENT (XENT) Down 49.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
XENTNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate